brentuximab vedotin
seagen,takeda
['brentuximab vedotin', 'hodgkin', 'lymphoma']
#asco22 | june 3 | oral abstract session | hematologic malignancies
"brentuximab vedotin and association with event-free survival in children with newly diagnosed high-risk hodgkin lymphoma"
presenter: sharon castellino, md, msc 
As Georgia's NCI Comprehensive Cancer Center, we are at the forefront of cancer research, innovation, and discovery. Request patient appointment: (888) 946-7447